What are the autoimmune risks associated with guselkumab therapy in patients with plaque psoriasis?
Abstract
The evidence indicates that guselkumab has a similar safety profile to placebo and adalimumab regarding adverse events, with limited data on specific autoimmune risks, underscoring further need for detailed long-term studies.
Fields of Study & Subjects
Psoriasis: Treatment and Pathogenesis
Spondyloarthritis Studies and Treatments
Dermatology and Skin Diseases
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 28 January 2026